Back to Search
MARK PEGRAM, M.D.
M.D.
Medical Oncology Physician
NPI: 1356361554Individual
Specialties, Licenses & Credentials
Internal Medicine Physician
Internal Medicine
Code: 207R00000X
A46221(CA)
Hematology & Oncology Physician
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
A46221(CA)
Surgical Oncology Physician
Surgery — Surgical Oncology
Code: 2086X0206X
A46221(CA)
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
A46221(CA)
Research & Publications (20)
Can we circumvent resistance to ErbB2-targeted agents by targeting novel pathways?
PMID 18777951·Clin Breast Cancer·2008
6-review
Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study.
PMID 16876287·Adv Drug Deliv Rev·2006
6-review
Results of two open-label, multicenter phase II studies of docetaxel, platinum salts, and trastuzumab in HER2-positive advanced breast cancer.
PMID 15150304·J Natl Cancer Inst·2004
3-trial
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer.
PMID 15150302·J Natl Cancer Inst·2004
7-preclinical
Combined biological therapy of breast cancer using monoclonal antibodies directed against HER2/neu protein and vascular endothelial growth factor.
PMID 12138395·Semin Oncol·2002
6-review
Combining the anti-HER2 antibody trastuzumab with taxanes in breast cancer: results and trial considerations.
PMID 11970740·Clin Breast Cancer·2001
6-review
Biological rationale for HER2/neu (c-erbB2) as a target for monoclonal antibody therapy.
PMID 11049052·Semin Oncol·2000
8-other
Trastuzumab and chemotherapeutics: drug interactions and synergies.
PMID 11236023·Semin Oncol·2000
8-other
Single-agent lapatinib for HER2-overexpressing advanced or metastatic breast cancer that progressed on first- or second-line trastuzumab-containing regimens.
PMID 19179558·Ann Oncol·2009
3-trial
Expert roundtable: emerging questions in ErbB2-positive breast cancer; February 22, 2007.
PMID 18777952·Clin Breast Cancer·2008
8-other
Phase I dose escalation and pharmacokinetic study of lapatinib in combination with trastuzumab in patients with advanced ErbB2-positive breast cancer.
PMID 18490651·J Clin Oncol·2008
3-trial
Biodistribution and predictive value of 18F-fluorocyclophosphamide in mice bearing human breast cancer xenografts.
PMID 18006620·J Nucl Med·2007
7-preclinical
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
PMID 19548375·Arch Pathol Lab Med·2007
6-review
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.
PMID 17159189·J Clin Oncol·2007
6-review
Augmented HER-2 specific immunity during treatment with trastuzumab and chemotherapy.
PMID 17785568·Clin Cancer Res·2007
8-other
HER2 targeted therapy in breast cancer...beyond Herceptin.
PMID 17899385·Rev Endocr Metab Disord·2007
6-review
Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status.
PMID 16896006·J Clin Oncol·2006
3-trial
Predicting chemotherapy response to paclitaxel with 18F-Fluoropaclitaxel and PET.
PMID 17138742·J Nucl Med·2006
7-preclinical
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
Via practice · 2 locations total
- Address
- 900 BLAKE WILBUR DR, 1ST FLOOR
PALO ALTO, CA 94304 - Phone
- (650) 498-6004
Quick Facts
- NPI
- 1356361554
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 4
- Locations
- 2
- Publications
- 20
Are you this provider?
Claim Your Profile